Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01452451 · ClinicalTrials.gov registry record · Phase 2

Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

A Phase 2 study of Diabetes Mellitus, sponsored by Hanmi Pharmaceutical Company Limited.

Completed
Registry status
Phase 2
Development phase
72
Enrollment target
1
Study location

NCT01452451 is a Phase 2 study of Diabetes Mellitus that has completed, run by Hanmi Pharmaceutical Company Limited. The registered enrollment target is 72 participants, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01452451, a Phase 2 study of Diabetes Mellitus, has completed, sponsored by Hanmi Pharmaceutical Company Limited.

COMPLETED
Registry status
Phase 2
Development phase
72 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to investigate the safety and tolerability of repeated doses of HM11260C when given different regimens in subjects with type 2 diabetes mellitus (T2DM) on stable metformin monotherapy.

Conditions Studied

Diabetes Mellitus

Interventions

  • DRUG Placebo
  • DRUG HM11260C

Study Locations (1)

Ohio

  • - Ohio City

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2011-12
Phase Phase 2

Sponsor

Hanmi Pharmaceutical Company Limited

25 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01452451

The ClinicalTrials.gov registry entry for NCT01452451 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (96% lower). The listed sponsor is Hanmi Pharmaceutical Company Limited, which has 25 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01452451 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT01452451 about?

NCT01452451 is a clinical study titled "Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus". The purpose of this study is to investigate the safety and tolerability of repeated doses of HM11260C when given different regimens in subjects with type 2 diabetes mellitus (T2DM) on stable metformin monotherapy.

What is the current status of trial NCT01452451?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2011-12.

What conditions does trial NCT01452451 study?

This clinical trial studies the following conditions: Diabetes Mellitus.

What interventions are being tested in trial NCT01452451?

The interventions under investigation include: Placebo (DRUG), HM11260C (DRUG).

Who is sponsoring clinical trial NCT01452451?

This trial is sponsored by Hanmi Pharmaceutical Company Limited, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01452451 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetes Mellitus

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.